Biotech Values

[DewDiligence]

Here’s MNTA’s own PR on the preliminary injunction. Note that a
trial date has not been set. At the hearing on 10/21/11, Amphastar’s
lawyer (unwisely, IMO—see #msg-68391526) told the Judge that
it would take his client one year to prepare for trial. Now that a PI
has been issued, the longer the better as far as MNTA is concerned.

http://finance.yahoo.com/news/Momenta-Pharmaceuticals-pz-4083772589.html?x=0&.v=1

›Momenta Pharmaceuticals Obtains Preliminary Injunction Against Amphastar Pharmaceuticals, Inc., Watson Pharmaceuticals, Inc. and International Medical Systems, Ltd.

Friday October 28, 2011, 4:47 pm EDT

CAMBRIDGE, Mass., Oct. 28, 2011 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that the United States District Court for the District of Massachusetts today entered an order enjoining Amphastar Pharmaceuticals, Inc., Watson Pharmaceuticals, Inc. and International Medical Systems, Ltd. [a wholly owned subsidiary of Amphastar] from offering to sell or selling their generic Lovenox before the District Court renders a decision in the on-going litigation relating to the U.S. Patent No. 7,575,886. No trial date has been set.

In granting the motion, the District Court found that Momenta Pharmaceuticals demonstrated a reasonable likelihood of success on the merits of their claim that Patent No. 7,575,886 is valid and infringed by the competitor's enoxaparin sodium product. The grant of the preliminary injunction is subject to appeal. [Amphastar’s Motion for an appeal has already been filed (#msg-68470614)]‹